ChemoCentryx (CCXI) announced preliminary results from a Phase 1b clinical trial evaluating its CCX872 in 50 pancreatic patients. The study aims to evaluate the safety and effects of orally administered CCX872 when added to the chemo regimen FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) in patients with advanced non-resectable pancreatic cancer over a treatment period of 12 weeks. Preliminary results show that CCX872 was well-tolerated and demonstrated a safety profile consistent with FOLFIRINOX alone.